Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01206309 · ClinicalTrials.gov registry record

Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation

A clinical trial of Graft Vs Host Disease and Bronchiolitis Obliterans, sponsored by Fred Hutchinson Cancer Center.

Completed
Registry status
911
Enrollment target
14
Study locations

NCT01206309: Completed study of Graft Vs Host Disease and Bronchiolitis Obliterans, sponsored by Fred Hutchinson Cancer Center.

NCT01206309 is a study of Graft Vs Host Disease and Bronchiolitis Obliterans that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 911 participants, above the 113-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (706% higher). The trial reports 14 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01206309, a study of Graft Vs Host Disease and Bronchiolitis Obliterans, has completed, sponsored by Fred Hutchinson Cancer Center.

COMPLETED
Registry status
911 participants
Enrollment target
14
Study locations

Study Summary

The purpose of this research study is to better understand the onset and course of graft versus host disease (GVHD)and other immune-mediated disorders after stem cell transplant.

Primary Outcome

The prevalence of: * Persistent, recurrent or late onset acute GVHD * Cutaneous Sclerosis * Bronchiolitis Obliterans Syndrome * Chronic GVHD

Study Locations (14)

New York

  • Roswell Park Cancer Institute - Buffalo
  • Weill Cornell Medical College - New York

Ohio

  • Cleveland Clinic Foundation - Cleveland
  • The Ohio State University - Columbus

Arizona

  • Mayo Clinic - Scottsdale

California

  • Stanford University - Stanford

Florida

  • H. Lee Moffitt Cancer Center - Tampa

Massachusetts

  • Dana Farber Cancer Institute - Boston

Minnesota

  • University of Minnesota - Minneapolis

Missouri

  • Washington University St. Louis - St Louis

Trial Details

FieldValue
Enrollment Target 911 participants
Start Date 2011-03
Est. Completion 2016-10
Fred Hutchinson Cancer Center

483 total trials

What the finished NCT01206309 record still lists

NCT01206309 is an observational study that tracks outcomes without assigning an intervention. The registered 911 participants enrollment target is mid-sized for trials with a published cap, above the 113-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (706% higher).

The record links to 3 conditions, with Graft Vs Host Disease appearing as the primary indexed condition, and to 0 interventions.

NCT01206309 lists 14 locations in 12 states (New York, Ohio, Arizona).

Frequently Asked Questions

What is clinical trial NCT01206309 about?

NCT01206309 is a clinical study titled "Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation". The purpose of this research study is to better understand the onset and course of graft versus host disease (GVHD)and other immune-mediated disorders after stem cell transplant.

What is the current status of trial NCT01206309?

This trial is currently completed. The enrollment target is 911 participants. The study started on 2011-03. Estimated completion is 2016-10.

What conditions does trial NCT01206309 study?

This clinical trial studies the following conditions: Graft Vs Host Disease, Bronchiolitis Obliterans, Cutaneous Sclerosis.

Who is sponsoring clinical trial NCT01206309?

This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01206309 being conducted?

This trial has 14 study locations across Arizona, California, Florida, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Graft Vs Host Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01206309's enrollment target sits among peer trials

911 2nd of 36 the highest of 36 other Graft Vs Host Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Graft Vs Host Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06216548 · 909 participants · NA

    E-PRIME For Children With Medical Complexity

  • NCT06131840 · 914 participants · Phase 1

    A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

  • NCT05658497 · 908 participants

    Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)

  • NCT05739955 · 918 participants · NA

    Impact of Enhanced Daily Disinfection on Environmental Contamination in Hospital Rooms

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01206309, the US trial registry maintained by the National Library of Medicine. NCT01206309 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.